Susceptibility of mantle cell lymphomas to reovirus oncolysis

Abstract Mantle cell lymphoma (MCL) an incurable B-cell, non-Hodgkin lymphoma (NHL) urgently requires new treatments. We assessed reovirus mediated oncolysis in a panel of human MCL cell lines. In vitro , we found the cytopathic effect of reovirus infection ranged from high to very limited and corre...

Full description

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 34; no. 1; pp. 100 - 108
Main Authors Alain, Tommy, Muzik, Huong, Otsuka, Shannon, Chan, Salina, Magliocco, Tony, Diaz, Roman, Forsyth, Peter A, Morris, Don, Bebb, Gwyn
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.2010
Subjects
Animals
Hematology, Oncology and Palliative Medicine
Humans
Hydrolysis
Lymphoma, Mantle-Cell - therapy
Mantle cell lymphoma
Mice
Oncolysis
Oncolytic Virotherapy
Ras activation
Reoviridae - physiology
Reovirus
SCID mice
Oncolysis
Ras activation
SCID mice
Reovirus
Mantle cell lymphoma
Online AccessGet full text

Cover

More Information
Summary:Abstract Mantle cell lymphoma (MCL) an incurable B-cell, non-Hodgkin lymphoma (NHL) urgently requires new treatments. We assessed reovirus mediated oncolysis in a panel of human MCL cell lines. In vitro , we found the cytopathic effect of reovirus infection ranged from high to very limited and correlated with levels of Ras activation. In vivo , a single reovirus injection intra-tumorally resulted in complete regression of both the injected and the contra-lateral tumor in a subcutaneous bi-tumor model, in one out of three cell lines tested. Reovirus treatment of MCL seems feasible but will need to be guided by the presence of molecular determinants of reovirus susceptibility.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2009.05.020